Limits...
Adherence to methotrexate in rheumatoid arthritis: a danish nationwide cohort study.

Bliddal H, Eriksen SA, Christensen R, Lorenzen T, Hansen MS, Østergaard M, Dreyer L, Luta G, Vestergaard P - Arthritis (2015)

Bottom Line: Conclusions.Treatment at hospital or in private practice did not influence the adherence to MTX.Nonmodifiable factors of importance were gender and age, while adherence to MTX therapy decreased with time lapse between diagnosis and prescription.

View Article: PubMed Central - PubMed

Affiliation: The Parker Institute, Department of Rheumatology, Copenhagen University Hospital at Bispebjerg and Frederiksberg, 2000 Copenhagen F, Denmark ; Department of Health Science and Technology, Center for Sensory-Motor Interaction (SMI), Aalborg University, 9220 Aalborg, Denmark.

ABSTRACT
Objectives. To study adherence to methotrexate (MTX) and factors of importance thereof in patients with rheumatoid arthritis (RA). Methods. Patients with a hospital diagnosis of RA (ICD10 codes M05.X or M06.X) after January 1, 1997, and aged ≥18 years at the date of first diagnosis/contact, with at least one prescription of MTX (L04AX03), were included. Results. A total of 18,703 (47.6%) patients had ever used MTX among 39,286 with a diagnosis of RA; among the MTX users, 16,503 (88.2%) had filed more than one MTX prescription. The median time from diagnosis to first MTX prescription was 0.66 (IQR 0.26-1.80) years. In those who filed more than one MTX prescription, the mean adherence time for ≥7.5 mg MTX per week was 1,925 (IQR 467-3,056) days for patients treated in private practice versus 1,892 (IQR 452-3,316) days for patients treated in hospital. The main determinants of nonadherence were female gender, younger age, and time from diagnosis to initiation of MTX. Conclusions. Treatment at hospital or in private practice did not influence the adherence to MTX. Nonmodifiable factors of importance were gender and age, while adherence to MTX therapy decreased with time lapse between diagnosis and prescription.

No MeSH data available.


Related in: MedlinePlus

Adherence to MTX. Use of 5 mg per week stratified by whether the patient was seen by a practicing specialist or not. Days from first prescription.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4355606&req=5

fig3: Adherence to MTX. Use of 5 mg per week stratified by whether the patient was seen by a practicing specialist or not. Days from first prescription.

Mentions: Figure 2 (including all prescriptions) and Figure 3 (only considering those who filed two or more MTX prescriptions) show the Kaplan-Meier plots of adherence to MTX stratified by whether they were seen by practising specialists in rheumatology or not. No difference in adherence to MTX was present between those managed in private practice (1,925 (IQR 467–3,056) days) versus 1,892 (IQR 452–3,316) days for patients treated in hospital. In those who filed more than one MTX prescription, the mean adherence time for 7.5 mg MTX per week was 2,245 (IQR 986–3,407) days.


Adherence to methotrexate in rheumatoid arthritis: a danish nationwide cohort study.

Bliddal H, Eriksen SA, Christensen R, Lorenzen T, Hansen MS, Østergaard M, Dreyer L, Luta G, Vestergaard P - Arthritis (2015)

Adherence to MTX. Use of 5 mg per week stratified by whether the patient was seen by a practicing specialist or not. Days from first prescription.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4355606&req=5

fig3: Adherence to MTX. Use of 5 mg per week stratified by whether the patient was seen by a practicing specialist or not. Days from first prescription.
Mentions: Figure 2 (including all prescriptions) and Figure 3 (only considering those who filed two or more MTX prescriptions) show the Kaplan-Meier plots of adherence to MTX stratified by whether they were seen by practising specialists in rheumatology or not. No difference in adherence to MTX was present between those managed in private practice (1,925 (IQR 467–3,056) days) versus 1,892 (IQR 452–3,316) days for patients treated in hospital. In those who filed more than one MTX prescription, the mean adherence time for 7.5 mg MTX per week was 2,245 (IQR 986–3,407) days.

Bottom Line: Conclusions.Treatment at hospital or in private practice did not influence the adherence to MTX.Nonmodifiable factors of importance were gender and age, while adherence to MTX therapy decreased with time lapse between diagnosis and prescription.

View Article: PubMed Central - PubMed

Affiliation: The Parker Institute, Department of Rheumatology, Copenhagen University Hospital at Bispebjerg and Frederiksberg, 2000 Copenhagen F, Denmark ; Department of Health Science and Technology, Center for Sensory-Motor Interaction (SMI), Aalborg University, 9220 Aalborg, Denmark.

ABSTRACT
Objectives. To study adherence to methotrexate (MTX) and factors of importance thereof in patients with rheumatoid arthritis (RA). Methods. Patients with a hospital diagnosis of RA (ICD10 codes M05.X or M06.X) after January 1, 1997, and aged ≥18 years at the date of first diagnosis/contact, with at least one prescription of MTX (L04AX03), were included. Results. A total of 18,703 (47.6%) patients had ever used MTX among 39,286 with a diagnosis of RA; among the MTX users, 16,503 (88.2%) had filed more than one MTX prescription. The median time from diagnosis to first MTX prescription was 0.66 (IQR 0.26-1.80) years. In those who filed more than one MTX prescription, the mean adherence time for ≥7.5 mg MTX per week was 1,925 (IQR 467-3,056) days for patients treated in private practice versus 1,892 (IQR 452-3,316) days for patients treated in hospital. The main determinants of nonadherence were female gender, younger age, and time from diagnosis to initiation of MTX. Conclusions. Treatment at hospital or in private practice did not influence the adherence to MTX. Nonmodifiable factors of importance were gender and age, while adherence to MTX therapy decreased with time lapse between diagnosis and prescription.

No MeSH data available.


Related in: MedlinePlus